Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines—A Case Series

Background: To describe cases of retinal vascular events shortly after administration of mRNA or adenoviral-vectored COVID-19 vaccines. Design: Retrospective, multicenter case series. Methods: Six cases of retinal vascular events shortly after receiving COVID-19 vaccines. Results: A 38-year-old, oth...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Christian Girbardt, Catharina Busch, Mayss Al-Sheikh, Jeanne Martine Gunzinger, Alessandro Invernizzi, Alba Xhepa, Jan Darius Unterlauft, Matus Rehak
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	post-vaccination COVID-19 vaccination vascular complication retinal vascular complication Medicine R
Acceso en línea:	https://doaj.org/article/11e6209e8f554c7194600457d9e60c43
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:11e6209e8f554c7194600457d9e60c43
record_format	dspace
spelling	oai:doaj.org-article:11e6209e8f554c7194600457d9e60c432021-11-25T19:11:32ZRetinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines—A Case Series10.3390/vaccines91113492076-393Xhttps://doaj.org/article/11e6209e8f554c7194600457d9e60c432021-11-01T00:00:00Zhttps://www.mdpi.com/2076-393X/9/11/1349https://doaj.org/toc/2076-393XBackground: To describe cases of retinal vascular events shortly after administration of mRNA or adenoviral-vectored COVID-19 vaccines. Design: Retrospective, multicenter case series. Methods: Six cases of retinal vascular events shortly after receiving COVID-19 vaccines. Results: A 38-year-old, otherwise healthy male patient presented with branch retinal arterial occlusion four days after receiving his second dose of SARS-CoV-2 vaccination with Comirnaty<sup>®</sup> (BioNTech<sup>®</sup>, Mainz, Germany; Pfizer<sup>®</sup>, New York City, NY, USA). An 81-year-old female patient developed visual symptoms twelve days after the second dose of SARS-CoV-2 vaccination with Comirnaty<sup>®</sup> and was diagnosed with a combined arterial and venous occlusion in her right eye. A 40-year-old male patient noticed blurry vision five days after his first dose of SARS-CoV-2 vaccination with Comirnaty<sup>®</sup> and was diagnosed with venous stasis retinopathy in his left eye. A 67-year-old male was diagnosed with non-arteritic anterior ischemic optic neuropathy in his right eye four days after receiving the first dose of Vaxzevria<sup>®</sup> (AstraZeneca<sup>®</sup>, Cambridge, UK). A 32-year-old man presented with a sudden onset of a scotoma two days after receiving the second dose of SARS-CoV-2 vaccination with Spikevax<sup>®</sup> (Moderna, Cambridge, UK) and was diagnosed with a circumscribed nerve fiber infarction. A 21-year-old female patient developed an acute bilateral acute macular neuroretinopathy three days after receiving the first dose of SARS-CoV2-vaccine Vaxzevria<sup>®</sup> (AstraZeneca<sup>®</sup>, Cambridge, UK). Conclusion: This case series describes six cases of retinal vascular events shortly after receiving mRNA or adenoviral-vectored COVID-19 vaccines. The short time span between received vaccination and occurrence of the observed retinal vascular events raises the question of a direct correlation. Our case series adds to further reports of possible side effects with potential serious post-immunization complications of COVID-19 vaccinations.Christian GirbardtCatharina BuschMayss Al-SheikhJeanne Martine GunzingerAlessandro InvernizziAlba XhepaJan Darius UnterlauftMatus RehakMDPI AGarticlepost-vaccinationCOVID-19 vaccinationvascular complicationretinal vascular complicationMedicineRENVaccines, Vol 9, Iss 1349, p 1349 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	post-vaccination COVID-19 vaccination vascular complication retinal vascular complication Medicine R
spellingShingle	post-vaccination COVID-19 vaccination vascular complication retinal vascular complication Medicine R Christian Girbardt Catharina Busch Mayss Al-Sheikh Jeanne Martine Gunzinger Alessandro Invernizzi Alba Xhepa Jan Darius Unterlauft Matus Rehak Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines—A Case Series
description	Background: To describe cases of retinal vascular events shortly after administration of mRNA or adenoviral-vectored COVID-19 vaccines. Design: Retrospective, multicenter case series. Methods: Six cases of retinal vascular events shortly after receiving COVID-19 vaccines. Results: A 38-year-old, otherwise healthy male patient presented with branch retinal arterial occlusion four days after receiving his second dose of SARS-CoV-2 vaccination with Comirnaty<sup>®</sup> (BioNTech<sup>®</sup>, Mainz, Germany; Pfizer<sup>®</sup>, New York City, NY, USA). An 81-year-old female patient developed visual symptoms twelve days after the second dose of SARS-CoV-2 vaccination with Comirnaty<sup>®</sup> and was diagnosed with a combined arterial and venous occlusion in her right eye. A 40-year-old male patient noticed blurry vision five days after his first dose of SARS-CoV-2 vaccination with Comirnaty<sup>®</sup> and was diagnosed with venous stasis retinopathy in his left eye. A 67-year-old male was diagnosed with non-arteritic anterior ischemic optic neuropathy in his right eye four days after receiving the first dose of Vaxzevria<sup>®</sup> (AstraZeneca<sup>®</sup>, Cambridge, UK). A 32-year-old man presented with a sudden onset of a scotoma two days after receiving the second dose of SARS-CoV-2 vaccination with Spikevax<sup>®</sup> (Moderna, Cambridge, UK) and was diagnosed with a circumscribed nerve fiber infarction. A 21-year-old female patient developed an acute bilateral acute macular neuroretinopathy three days after receiving the first dose of SARS-CoV2-vaccine Vaxzevria<sup>®</sup> (AstraZeneca<sup>®</sup>, Cambridge, UK). Conclusion: This case series describes six cases of retinal vascular events shortly after receiving mRNA or adenoviral-vectored COVID-19 vaccines. The short time span between received vaccination and occurrence of the observed retinal vascular events raises the question of a direct correlation. Our case series adds to further reports of possible side effects with potential serious post-immunization complications of COVID-19 vaccinations.
format	article
author	Christian Girbardt Catharina Busch Mayss Al-Sheikh Jeanne Martine Gunzinger Alessandro Invernizzi Alba Xhepa Jan Darius Unterlauft Matus Rehak
author_facet	Christian Girbardt Catharina Busch Mayss Al-Sheikh Jeanne Martine Gunzinger Alessandro Invernizzi Alba Xhepa Jan Darius Unterlauft Matus Rehak
author_sort	Christian Girbardt
title	Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines—A Case Series
title_short	Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines—A Case Series
title_full	Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines—A Case Series
title_fullStr	Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines—A Case Series
title_full_unstemmed	Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines—A Case Series
title_sort	retinal vascular events after mrna and adenoviral-vectored covid-19 vaccines—a case series
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/11e6209e8f554c7194600457d9e60c43
work_keys_str_mv	AT christiangirbardt retinalvasculareventsaftermrnaandadenoviralvectoredcovid19vaccinesacaseseries AT catharinabusch retinalvasculareventsaftermrnaandadenoviralvectoredcovid19vaccinesacaseseries AT mayssalsheikh retinalvasculareventsaftermrnaandadenoviralvectoredcovid19vaccinesacaseseries AT jeannemartinegunzinger retinalvasculareventsaftermrnaandadenoviralvectoredcovid19vaccinesacaseseries AT alessandroinvernizzi retinalvasculareventsaftermrnaandadenoviralvectoredcovid19vaccinesacaseseries AT albaxhepa retinalvasculareventsaftermrnaandadenoviralvectoredcovid19vaccinesacaseseries AT jandariusunterlauft retinalvasculareventsaftermrnaandadenoviralvectoredcovid19vaccinesacaseseries AT matusrehak retinalvasculareventsaftermrnaandadenoviralvectoredcovid19vaccinesacaseseries
_version_	1718410137452937216

Retinal Vascular Events after mRNA and Adenoviral-Vectored COVID-19 Vaccines—A Case Series

Ejemplares similares